ReviewFrontiers in pharmacology2022
Molecular Mechanism of Anti-Colorectal Cancer Effect of
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Article
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- TMT-based proteomics analysis identifies RPLP1 as a key protein target in ursolic acid Inhibition of colorectal cancer.Discover oncology · 2025Article
- Unveiling the mechanisms of Tianjihuang in hepatocellular carcinoma: a network pharmacology and molecular docking study.Discover oncology · 2025Article
- Network pharmacology mechanisms and experimental verification ofFrontiers in oncology · 2025Article
- The immunotherapy mechanism of Hedyotis Diffusae Herba in treating liver cancer: a study based on network pharmacology, bioinformatics, and experimental validation.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Article
- Network pharmacology, bioinformatics, and experimental validation to identify the role ofHeliyon · 2024Article
- Induction of ferroptosis by natural products in non-small cell lung cancer: a comprehensive systematic review.Frontiers in pharmacology · 2024Review
- Molecular Targets and Mechanisms of Hedyotis diffusa Willd. for Esophageal Adenocarcinoma Treatment Based on Network Pharmacology and Weighted Gene Co-expression Network Analysis.Current drug targets · 2024Article
- Molecular mechanism of the treatment of lung adenocarcinoma byFrontiers in pharmacology · 2024Article
- Anti-tumor Effects ofIranian journal of pharmaceutical research : IJPRArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the sharp change in our diet and lifestyle, the incidence of colorectal cancer (CRC) is increasing among young people and has become the second most common malignant tumor worldwide. Although the current treatment of CRC is getting updated rapidly, recurrence and metastasis are still inevitable. Therefore, new anticancer drugs are needed to break existing limitations. In recent years,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.